



In their letter to EHP, Huffet al. (1) main-
tained that arsenic is still viewed as "a para-
doxical carcinogen; that is, carcinogenic to
humans but not to laboratory animals," and
that this paradox will be believed until car-
cinogenicity of arsenic is demonstrated in
animal experiments such as "long-term
inhalation studies usingarsenic trioxide."
Huffet al. (1) seem not to take into con-
sideration, however, that a researcher never
has at his disposal an animal population com-
mensurable with human populations for
which even low carcinogenic risk may be
attributed to an exposure, based on epidemi-
ologic data, with asufficient statistical signifi-
cance. Even under carcinogenic exposure,
even most common cancers are still rather
rare events. For example, an additional 50
lung cancers per 100,000 workers exposed to
arsenic trioxide aerosol in copper smelters
would constitute a very high risk level, while
probably no cancer would be detected after
exposing 100 rats to the same aerosol, pro-
vided the risk is the same. To attempt to cir-
cumvent this statistical obstacle, we might
expose rats to much higher concentrations of
M20 but undersuch an exposure,develop-
ment ofasevere intoxication would be highly
probable, and rats with a dramatically short-
ened life span might never survive until the
appearance ofcancer. The same argument is
valid ifdrinking water is used as the medium
for administering arsenic.
It seems much wiser to use experimental
models, giving opportunity to concentrate a
sufficiendy high and long-term exposure on a
small part ofa target organ only, thus reducing
systemic toxicity of the tested chemical to a
minimum. Ofcourse, such a model would be
difficult to use directly for anystandard setting,
but it would be adequate for proving that the
chemical iscarcinogenic (atleastforoneorgan).
Twelve years ago we published results of
such an experiment (2), which Huff et al.
(1) failed to mention in their briefoverview.
The English version of the summary of our
paper (verbatim as translated by the publish-
ers) is as follows:
Out of 18 albino rats which survived
17-24 months after implantation in a partially
isolated glandular stomach compartment of a
perforated polyethylene capsule containing 8
mg arsenic trioxide in a fat wax mixture as vehi-
cle, two developed muconodular adenocarcino-
ma and one - mucoid cystic adenocarcinoma in
that gastric compartment; metastasis in the liver
was detected in one animal. No malignant
tumors were found in 9 rats with the same post-
surgical survival time after implantation of a
control capsule containing the same mixture
without arsenic. Since spontaneous gastric can-
cers virtually fail to appear in laboratory rats,
nor have they ever been reported by other
authors after control capsule implantation but
developed in some rats after implantation of a
carcinogen-containing one, the results of the
present investigation may be interpreted as an
experimental proof of the carcinogenicity of
arsenic which was previously assumed on epi-
demiologic evidence.
Bullock and Curtis (3) reported one gas-
tric cancer per 33,000 rats. Anisimov et al.
(4) found 63 spontaneous malignant tumors
but no gastric cancer in 443 rats (average age
723 ± 16 days for 213 males and 735 ± 14
days for 230 females) bred at the same farm
from which our ratswere obtained.
We also obtained one gastric cancer from
rats implanted with calcium arsenate and one
from those implanted with natural arsenopy-
rite (5). The latter is ofa special interest, as it
was demonstrated in an epidemiologic study
that the higher the arsenic content (mainly as
the arsenopyrite) in the ore deposits and in
mine dusts, the higher the cancer mortality in
gold-miners (5).
It is a pity that language and other barri-
ers made our papers unknown to Western
colleagues, but it is never too late to learn.
Boris A. Katsnelson
Medical Research Center for Prophylaxis and
Health Protection in Industrial Workers
Ekaterinburgh, Russia
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Arsenic: Evidence of
Carcinogenicity in Animals
We aregrateful to Katsnelson for reminding us
about his paper on arsenic implantation and
local gastric cancer published some 12 years
ago (1). We were indeed aware oftheir pub-
lished work, which was contained and summa-
rized in an I4RCMonographs carcinogenicity
evaluation of arsenic (2), and cited in our
review (3).
However, while the collective evidence of
carcinogenicty on arsenic appears quite close
to being considered sufficient evidence in
experimental animals (2-4), an adequate and
definitive long-term (30+ months) experi-
ment on arsenic (and specifically arsenic triox-
ide) has not yet been done, especially not by
inhalation. We believe this should be accom-
plished to settle the debate whether arsenic is
the only human carcinogen that has not been
shown to likewise convincingly cause cancer
in laboratory animals. Further, the argument
that inorganic arsenic is a multiorgan carcino-
gen in humans that will not be carcinogenic
in animals because of differences between
humans and rodents in methylation detoxifi-
cation capabilities has yet to be proven.
Arsenic is clastogenic in both humans and
animals, and mechanistically, arsenic appears
to be a late stage carcinogen (5,6).
Regarding alleged "paradoxical" carcino-
gens, in the 1970s and 1980s arsenic and ben-
zene, long considered carcinogenic in humans
(4,7-9), were touted as being exceptions to
the animal-human paradigm and were thus
used to discredit bioassays because of posed
nonconcordance with respect to a lack ofcar-
cinogenicity in animals. Perhaps similar to
arsenic, nearly 16 bioassays had been done on
benzene with little or no evidence ofcarcino-
genicity in animals. Yet, until Maltoni and
colleagues (10,11) and Huff et al. (12)
showed unequivocally that benzene is a
potent multispecies, multistrain, multisite car-
cinogen, many indicated that long-term
bioassay results were not relevant to human
cancer risks. Thus, should arsenic be consid-
ered as the only known human carcinogen
with less than sufficient correlative evidence
ofcarcinogenicity in animals? The scientifical-
ly appropriate answer is "no," not because
arsenic is not carcinogenic to animals, but
simply because definitive studies have not yet
been done to unequivocally answer the ques-
tion. Conversely, we know that for nearly 30
agents the evidence ofcarcinogenicty was first
observed in animals (and unheeded) and only
subsequently detected in humans (13,14). In
fact, all known human carciongens that have
been tested adequately are also carcinogenic
to animals (15-17).
Experimental carcinogenicity studies on
arsenic, so far, have been either inadequately
done (short duration, incomplete reporting,
limited pathology), poorly designed (inap-
propriate or no controls), or any marginally
positive results have been confounded by
other experimental factors (2,3,18). Few rel-
evant studies have been reported since the
last International Agency for Research on
Cancer (IARC) evaluation ofarsenic in 1987
(19-22), and these were primarily con-
cerned with arsenic as a tumor promoter or
in combination with other agents. None of
these studies are considered adequate for
determining whether arsenic, as a single
agent, is carcinogenic to animals (3, 23).
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Thus, despite Katsnelson's interesting
model for testing arsenic for carcinogenicity
and his findings of a few unusual applica-
tion-site gastric tumors, we remain uncon-
vinced that the collective experimental find-
ings on arsenic can be taken as proof that
arsenic is carcinogenic to animals; by this we
mean, on the singular basis of the available
animal data (and, for the moment, ignoring
the human data), that neither IARC nor the
National Toxicology Program (NTP) would
judge arsenic as a "probable" or "reasonably
anticipated" human carcinogen. The available
animal data alone simply do not meet the cri-
teria for either IARC or the NTP to consider
the laboratory evidence as being adequate and
sufficient to list arsenic as a likely carcinogen
to humans. Of course, both organizations do
consider arsenic and arsenic compounds as
being unequivocally carcinogenic to humans




Research Triangle Park, NC
MichaelWaalkes
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Independent Review of
Industry-generated Data
The commentary ofGibson et al. (1) ofDow
AgroSciences takes issue with our estimates of
potential risks to children from indoor broad-
cast uses ofchlorpyrifos (2) that were derived
from a recent study by Gurunathan et al. (3)
at the Environmental and Occupational
Health Sciences Institute (EOHSI) of
Rutgers University. Specifically, the Dow
AgroSciences researchers claim that potential
indoor exposures ofchlorpyrifos are "approx-
imately 10 times below" those found in the
EOHSI study.
Unfortunately, there is no easy way to
examine the claim made by Gibson et al. (1)
because most of the pertinent data on which
their statement is based are not available in
the peer-reviewed, published literature. Thus,
we are unable to determine whether the test
protocols or exposure time periods used in
the previous unpublished Dow studies are
comparable to the experimental approaches
used in the EOHSI study. For example,
Gibson and colleagues' citation of biomoni-
toring data ofvolunteers (simulating childlike
activities) following broadcast spraying of
chlorpyrifos-demonstrating potential child-
hood exposures to be 10-fold below EOHSI
estimates-is based entirely on one internal,
unpublished Dow Chemical Company study
(4). Similarly, Dow AgroSciences' exposure
study after "crack and crevice" treatment by
chlorpyrifos for insect infestation is based on
an industry-sponsored study whose results
were only recently published (5).
On the other hand, Gurunathan et al. (3)
presented a detailed and well-conducted
assessment ofexposures to chlorpyrifos over a
2-week period following a one-time broad-
cast application of chlorpyrifos by a licensed
pesticide applicator. Most published studies
in the past that examined exposure levels
related to broadcast spraying of chlorpyrifos
did not measure the pesticide's indoor con-
centration beyond 1 or 2 days following
applications [for example, see Fenske et al.
(6)]. What the EOHSI study showed was
that chlorpyrifos, like other semiviolatile pes-
ticides, did not dissipate or settle down, but
continued to vaporize into the gas phase and
resettle on a variety of solid surfaces indoors
(such as children's toys) over an extended
period oftime.
Furthermore, the experimental protocols
used in the EOHSI study (3) simulated con-
ditions that may easily lead to an underesti-
mation of exposure to indoor uses of chlor-
pyrifos. As we stated in our commentary (2),
in a number offacilities where many children
are present
... such as day care centers, schools, and
homes, where chlorpyrifos-based products may
befrequendysprayed on to control insect infesta-
tions, there can be cumulative exposures that are
much higher than those currently estimated from
the [EOSHI] and other pesticide exposure stud-
ies based on single [broadcast] applications.
This exchange raises two pressing issues
for public policy. First, those in the public and
private sectors charged with developing
national guidelines and standards to protect
children from environmental hazards often
make decisions based on incomplete informa-
tion. Secondly, we agree with Gibson et al. (1)
that a weight-of-evidence approach is the best
way to resolve issues involving the safety of
widely used compounds such as chlorpyrifos.
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